USMLE Step 1 practice question: Phenytoin zero-order (Michaelis-Menten) elimination kinetics
USMLE Step 1PharmacologyPharmacology
Which of the following best explains the disproportionate increase in this patient's serum drug concentration?
- Displacement of the drug from plasma albumin binding sites
- Reduced renal tubular secretion of the unchanged drug
- Inhibition of its metabolizing enzyme by a coadministered drug
- Saturation of its hepatic metabolizing enzymes within the therapeutic range
- Accumulation of a pharmacologically active hepatic metabolite
Show answer and explanation
Correct answer: D. Saturation of its hepatic metabolizing enzymes within the therapeutic range
This patient has phenytoin toxicity (nystagmus, ataxia, dysarthria, diplopia) after a modest dose increase. A 33% increase in dose (300 → 400 mg/day) produced a nearly 3-fold increase in serum concentration (11 → 31 µg/mL). With first-order (linear) kinetics, steady-state concentration is directly proportional to the dosing rate, so the expected new level would have been about 15 µg/mL.
Phenytoin is eliminated almost entirely by hepatic metabolism (mainly CYP2C9, with a smaller contribution from CYP2C19), and these enzymes have a Michaelis constant (Km) that lies within or below the therapeutic concentration range. According to Michaelis-Menten kinetics, the rate of elimination = Vmax × C / (Km + C). When C is well below Km, elimination is proportional to concentration (first-order kinetics: a constant fraction of drug is eliminated per unit time). As C rises above Km, the enzymes become saturated and elimination approaches Vmax, a constant amount per unit time (zero-order kinetics). Small increases in dose then cause disproportionately large increases in steady-state concentration, the apparent half-life lengthens, and the time to reach a new steady state is prolonged. For this reason, phenytoin doses are increased in small increments (eg, 25–50 mg/day) with close monitoring of serum levels. Other drugs with clinically important zero-order (saturable) elimination include ethanol and high-dose aspirin.
High-yield summary: Zero-order elimination = constant AMOUNT per unit time (phenytoin, ethanol, high-dose aspirin—‘PEA’); first-order elimination = constant FRACTION per unit time. Saturable kinetics → small dose increase, large rise in level. In hypoalbuminemia, the free fraction of phenytoin rises, so free levels should be measured.
Why the other options are wrong
- A. Displacement of the drug from plasma albumin binding sites — Displacement from albumin (eg, by valproate or uremia) or hypoalbuminemia increases the free fraction, but the total concentration stays the same or decreases; this patient has normal albumin, no interacting drugs, and a markedly increased total concentration.
- B. Reduced renal tubular secretion of the unchanged drug — Phenytoin is cleared almost exclusively by hepatic metabolism, with <5% excreted unchanged in the urine, and this patient's renal function is normal.
- C. Inhibition of its metabolizing enzyme by a coadministered drug — Inhibitors of CYP2C9 (eg, fluconazole, amiodarone, trimethoprim-sulfamethoxazole) can raise phenytoin levels, but this patient takes no other medications or supplements.
- E. Accumulation of a pharmacologically active hepatic metabolite — Phenytoin is metabolized mainly to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH), which is pharmacologically inactive; toxicity reflects the concentration of the parent drug, which is what was measured.
Key point
Phenytoin undergoes saturable (Michaelis-Menten) hepatic metabolism, so near the therapeutic range elimination shifts to zero-order kinetics and small dose increases cause disproportionate rises in serum concentration.
Memory hook
Zero-order trio ‘PEA’ (Phenytoin, Ethanol, Aspirin)—a pea is round like a 0: a little more dose, a lot more level.
15 free bank questions a day, exam-length timed blocks, spaced repetition and 3D anatomy — in English and Russian.
Play free